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Cerebral small vessel disease (SVD) is a major contributor to stroke, and a leading
cause of cognitive impairment and dementia. Despite the devastating effects of cerebral
SVD, the pathogenesis of cerebral SVD is still not completely understood. Moreover,
there are no specific pharmacological strategies for its prevention or treatment. Cerebral
SVD is characterized by marked functional and structural abnormalities of the cerebral
microcirculation. The clinical manifestations of these pathological changes include
lacunar infarcts, white matter hyperintensities, and cerebral microbleeds. The main
purpose of this review is to discuss evidence implicating oxidative stress in the
arteriopathy of both non-amyloid and amyloid (cerebral amyloid angiopathy) forms of
cerebral SVD and its most important risk factors (hypertension and aging), as well as
its contribution to cerebral SVD-related brain injury and cognitive impairment. We also
highlight current evidence of the involvement of the NADPH oxidases in the development
of oxidative stress, enzymes that are a major source of reactive oxygen species in
the cerebral vasculature. Lastly, we discuss potential pharmacological strategies for
oxidative stress in cerebral SVD, including some of the historical and emerging NADPH
oxidase inhibitors.
Keywords: cerebral small vessel disease, oxidative stress and redox regulation, NADPH oxidases (Noxs), brain
injury, cognitive impairment, pharmacological strategies
INTRODUCTION
Cerebral small vessel disease (SVD) is the term currently used to pathological processes that affect
the brain parenchymal circulation (arterioles, capillaries, and veins). Brain parenchymal arterioles
are an important site of vascular resistance (Faraci, 2011) and are crucial for maintaining adequate
blood flow to the sub-surface brain structures (Bullmore and Sporns, 2012). The brain requires a
disproportionate amount of the body’s energy. Despite accounting for only 2% of body mass, up to
20% of cardiac output is devoted to meeting the brain’s energy demands (Attwell et al., 2010). In
order to deliver these nutrients effectively and protect the brain from hypoperfusion and ischemic
damage, the cerebral vasculature possesses well-developed mechanisms that enable cerebral blood
flow (CBF) to remain constant during fluctuations in arterial pressure (autoregulation) and to meet
the increased nutrient demands when local brain activity rises (neurovascular coupling; Cipolla,
2009; Jackman and Iadecola, 2014; De Silva and Faraci, in press). Cerebral SVD significantly and
chronically impairs the ability of the cerebral vasculature to meet these demands due to a number
of structural and functional changes, which ultimately result in brain injury, cognitive decline, and
dementia.
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Cerebral SVD takes an enormous toll on the individual and is
a major burden on the healthcare system. It not only accounts for
20–30% of all strokes (Pantoni, 2010), but significantly increases
the risk of future stroke (Vermeer et al., 2007; Debette and
Markus, 2010). Furthermore, cerebral SVD is thought to account
for about 45% of dementia cases (Gorelick et al., 2011). Cerebral
SVD is more prevalent in the elderly. As such, efforts to study
and develop treatments for cerebral SVD need to be intensified
in order to reduce both the social and economic burden of the
disease as our population ages.
In this review, we will discuss the clinical features, pathological
changes, and impact of cerebral SVD on the brain and its
vasculature. We will briefly discuss the two most common
categories of SVD, non-amyloid and amyloid forms. We will
then discuss oxidative stress and the potential role it may play
in the arteriopathy of cerebral SVD, as well as its role in
cerebral SVD-related brain injury and cognitive impairment.
Also, we will highlight evidence implicating the NADPH oxidases
as key contributors to the development of oxidative stress.
Finally, we will discuss the therapeutic agents including anti-
oxidant strategies, and their potential use for the treatment of
cerebral SVD.
WHAT IS CEREBRAL SMALL VESSEL
DISEASE?
Non-Amyloid Cerebral SVD
The clinical manifestations of cerebral SVD vary depending on
the specific cause of the disease (i.e., sporadic vs. monogenic
origin) as well as the brain region(s) affected. Individuals
may present with sudden onset stroke symptoms, changes in
cognitive function, progressive cognitive deterioration, dementia,
depression and physical disability (Chabriat et al., 1995; van der
Flier et al., 2005; Inzitari et al., 2009; de Laat et al., 2011). It
is thought that parenchymal arterioles, capillaries and venules
are the preferential target of cerebral SVD. As these vessels
are difficult to directly assess in patients in vivo (Wardlaw
et al., 2001), diagnosis relies on a range of clinical, cognitive,
neuroimaging, and neuropathological tests. The majority of cases
of cerebral SVD are sporadic, with aging and hypertension
thought to be the most important risk factors. A number of
hereditary forms of cerebral SVD have also been identified
(See Haffner et al., 2015 for discussion). The difficulty in
studying small cerebral vessels has likely contributed to the lack
of understanding of the disease and absence of any specific
pharmacological strategies for its treatment.
Cerebral SVD induces a number of pathological changes to
the vasculature. In small arterioles, this may include marked
vascular muscle dysfunction, lipohyalinosis, vascular remodeling,
and deposition of fibrotic material. Basement membranes can
also become thickened and perivascular spaces enlarged. There
may also be disruption of the blood-brain barrier (BBB) leading
to edema (Taheri et al., 2011). Venous structure is also affected
with collagen being deposited in the walls of venules (venous
collagenosis; Moody et al., 1995). These diverse changes to the
cerebral microvasculature result in reduced CBF (resulting in
chronic hypoperfusion) and a loss of adaptive responses (e.g.,
autoregulation and neurovascular coupling). As a result the
ability to adequately supply the brain with the required nutrients
is significantly impaired, resulting the profound tissue damage.
Diagnosis of cerebral SVD relies in large part on neuroimaging
findings. Wardlaw et al. (2013) has described in detail the
changes that occur in the brain during sporadic cerebral SVD
and the use of imaging techniques to detect these changes.
The features that can be detected using imaging techniques
such as magnetic resonance imaging (MRI) include lacunar
infarcts/hemorrhages, white matter hyperintensities (WMH),
dilated perivascular spaces, and brain atrophy (Doubal et al.,
2010; Rost et al., 2010; Jokinen et al., 2011; Aribisala et al.,
2013; Potter et al., 2015). Use of more advanced MRI techniques
reveals further brain injury including brain edema, and further
alterations to white matter (Bastin et al., 2009; Maclullich et al.,
2009). One of the difficulties in diagnosing cerebral SVD is that
these markers are not specific for SVD alone. For example, the
presence of WMH is not restricted to cerebral SVD, and lacunar
infarcts may occur due to an embolism (Jackson et al., 2010;
Potter et al., 2012). Therefore, clinicians rely on the presence of
a number of these features for proper diagnosis of the disease.
The etiology of cerebral SVD is incompletely understood.
Cardiovascular risk factors such as hypertension and aging are
thought to be important contributors to late life dementia (Hall
et al., 2005; Kivipelto et al., 2006; Gottesman et al., 2014).
Such risk factors are likely to worsen disease progression via
deleterious effects on both the structure and functioning of
cerebral blood vessels. Another thought provoking hypothesis is
that failure of the BBB, leading to extravasation of toxic plasma
components (Silberberg et al., 1984), may be an important factor
in cerebral SVD. BBB disruption is linked with brain injury
caused by a number of neurological conditions including stroke,
multiple sclerosis, and Alzheimer’s disease. Wardlaw et al. (2013)
proposed that endothelial cell failure during cerebral SVD would
lead to extravasation of toxic plasma components resulting in
localized damage to both the blood vessel and brain parenchyma.
Additional research is needed to fully define the role of BBB
failure in the pathogenesis of cerebral SVD.
Interestingly, while cerebral SVD primarily affects the
microvasculature, it has been suggested that larger arteries may
also contribute to the disease process (Xu, 2014). Specifically,
lacunar strokes may occur as a result of atheroma or cardiac
embolism (Wardlaw et al., 2013). Furthermore, increased arterial
stiffness has been shown to be associated with an increased white
matter lesion burden (Poels et al., 2012). Therefore, while the
microvasculature is the primary target of SVD, the contribution
of larger arteries should not be immediately discounted.
Amyloid Cerebral SVD
Cerebral amyloid angiopathy (CAA) is a common form of
cerebral SVD and refers to the deposition of amyloid β-peptide
(Aβ) in the walls of cerebral leptomeningeal and parenchymal
arteries, and arterioles. CAA is a frequent observation in the
elderly, appearing in ∼10–30% of brain autopsies and 50–80%
of people with dementia (Jellinger and Attems, 2010). CAA is
most commonly recognized as a cause of hemorrhagic stroke,
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however, evidence indicates that CAA is also an important
contributor to cognitive impairment and dementia (Gorelick
et al., 2011). Moreover, CAA is associated with a high prevalence
of WMH and cortical microinfarcts, which are assumed to be
of ischemic origin (Haglund and Englund, 2002; van Horssen
et al., 2005; De Reuck et al., 2011). Mechanisms linking CAA
and brain injury, whether that be hemorrhagic or ischemic in
nature, are not completely understood, however, they are likely
to involve both structural and functional abnormalities of the
cerebral vasculature. For example, in advanced cases, CAA can
cause structural changes such as concentric splitting, loss of
smooth muscle cells, and fibrinoid necrosis, which may increase
the propensity for vessel rupture and thus hemorrhage. Clinical
and experimental evidence indicates that deposition of Aβ in the
vessel wall can also cause functional abnormalities (e.g., impaired
vasodilator responses and autoregulation; Smith et al., 2008; Park
et al., 2014a), which may impair brain perfusion, reduce vascular
reserve, and ultimately increase the propensity to ischemic injury.
In support of this notion, mice with advanced CAA develop larger
infarcts and greater deficits in CBF after transient ischemic stroke
(Milner et al., 2014). Evidence, albeit largely from experimental
studies, indicates that Aβ may cause cerebral vascular dysfunction
even in the absence of vascular deposition (Niwa et al., 2002;
Park et al., 2005). Thus, disruptions in the functioning of cerebral
vessels by soluble Aβ might be an early event in CAA.
Although CAA is usually observed in large cerebral vessels and
arterioles, Aβ depositions can also occur in capillaries (capillary
CAA; Attems, 2005). In light of the deleterious effects of Aβ
on large vessels and arterioles, it is not surprising therefore to
find that Aβ accumulation in capillaries affects BBB integrity.
Indeed, BBB leakage and a loss of tight junction proteins
occur in patients with CAA (Carrano et al., 2011; Hartz et al.,
2012). Experimental studies also provide evidence that Aβ can
promote BBB disruption. For example, exogenous Aβ triggers
tight junction disruption, cell death, and hyperpermeability of
cultured rodent and human brain endothelial cells (Marco and
Skaper, 2006; Gonzalez-Velasquez et al., 2008; Carrano et al.,
2011; Hartz et al., 2012). Also, microvessels of mice with CAA
display increased BBB permeability (Lee et al., 2005; Hartz et al.,
2012; Kruyer et al., 2015). In addition to its effects on endothelial
cells of the BBB, Aβ might have deleterious effects on other cells
of the neurovascular unit. For example, exogenous Aβ induces
death of cultured human brain pericytes (Verbeek et al., 1997;
Bruinsma et al., 2010), and pericyte loss is evident in mice with
advanced CAA (Park et al., 2014a).
REACTIVE OXYGEN SPECIES AND
CEREBRAL VASCULAR FUNCTION
ROS Generation in the Vasculature
Reactive oxygen species (ROS) are a group of oxygen-derived
molecules generated by all mammalian cells. The conversion
of molecular oxygen to superoxide by oxidase enzymes is
the first step in the generation of all ROS. Superoxide can
be converted either enzymatically [by superoxide dismutases
(SOD)] or spontaneously to the non-radical hydrogen peroxide.
Furthermore, hydrogen peroxide can be generated directly by
some enzymes (e.g., the NADPH oxidases; Dikalov et al.,
2008). Hydrogen peroxide is chemically more stable than
superoxide and can easily cross cellular membranes. As such,
hydrogen peroxide may be the most important ROS in terms
of physiological cell signaling. Glutathione peroxidase (Gpx) or
catalase enzymatically metabolize hydrogen peroxide to water
and oxygen. During physiological conditions, the production
and metabolism of ROS by anti-oxidants is tightly regulated
in order to prevent cellular damage. Under these conditions,
ROS may serve as important signaling molecules for the
regulation of vascular tone (Miller et al., 2005, 2006; Paravicini
et al., 2006). Numerous stimuli can, however, disrupt the
oxidant/anti-oxidant balance and the ultimate effect is one where
oxidants overwhelm anti-oxidants resulting in oxidative stress.
Compelling evidence indicates that oxidative stress underlies
cerebral vascular dysfunction associated with a number of
vascular-related diseases (see Oxidative stress and cerebral
vascular dysfunction).
NADPH Oxidases: A Key Source of ROS
in the Cerebral Vasculature
Cerebral arteries express a number of enzymes that are potential
sources of ROS including cyclooxygenase (COX), mitochondria,
and the NADPH oxidases. COX is an important source of
vascular ROS in cerebral arteries (Kontos et al., 1984, 1990;
Didion et al., 2001). COX generates superoxide during the
conversion of arachidonic acid to prostaglandin H2, which is
the precursor for many vasoactive prostanoids. Therefore, the
ROS generated by COX is a by-product of its normal function.
Mitochondria generate ROS during oxidative phosphorylation
and are another important source of ROS in the vasculature
(Busija and Katakam, 2014). Cerebral endothelial cells contain
a relatively high density of mitochondria (Oldendorf et al.,
1977), which may in part reflect the high metabolic demands
of maintaining the BBB. As with COX, mitochondrial-derived
ROS are by-products of its normal function. It has been
suggested that endothelial NO synthase (eNOS) can switch from
generating NO to superoxide when it is “uncoupled.” Studies
have shown that reduced bioavailability of tetrahydrobiopterin,
a requisite cofactor for eNOS activity, results in eNOS-dependent
superoxide production, rather than NO (Santhanam et al., 2012,
2014).
As is discussed above, COX, mitochondria and eNOS generate
ROS as a by-product of their normal enzymatic function or
in a dysfunctional state. In contrast, the NADPH oxidases
are the only known family of enzymes that generate ROS as
their primary function (Drummond et al., 2011). The NADPH
oxidase is a heteromultimeric enzyme complex with up to six
separate subunits. Nox2-NADPH oxidase or gp91phox was the
first NADPH oxidase to be discovered in neutrophils, where
this enzyme plays a central role in immunological host defense
(Babior et al., 2002). Since this discovery, a number of other
NADPH oxidase isoforms have been identified, namely Nox1-,
Nox3-, Nox4-, and Nox5-NADPH oxidases. The structure and
functioning of the Nox isoforms have been comprehensively
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reviewed (Selemidis et al., 2008; Drummond et al., 2011;
Lassegue et al., 2012) and thus will not be discussed here.
With respect to the cerebral circulation, Nox1, Nox2, and
Nox4 catalytic subunits, as well as cytoplasmic subunits (e.g.,
p47phox, p67phox), are expressed at the mRNA and protein
level (Kazama et al., 2004; Paravicini et al., 2004; Ago et al.,
2005; Miller et al., 2007). Notably, Nox4 appears to be the
most abundant isoform in cerebral arteries (during health)
followed by Nox1 and finally Nox2 (Ago et al., 2005). Substantial
evidence indicates that the NADPH oxidases are functionally
active in cerebral arteries, and are a major source of ROS in
cerebral arteries during health (Didion and Faraci, 2002; Park
et al., 2004a; Miller et al., 2005). Moreover, compelling evidence
indicates that excess production of superoxide by these enzymes
underlies the oxidative stress and cerebral vascular dysfunction
that is associated a number of vascular-related diseases (e.g.,
hypertension, diabetes, hypercholesterolemia) and also advanced
age (Mayhan et al., 1990; Girouard et al., 2006; Kitayama et al.,
2007; Miller et al., 2010).
Roles of ROS and the NADPH Oxidases
in Regulating Cerebral Vascular Function
In blood vessels from healthy animals (e.g., mouse, rat, pig,
and rabbit), NADPH oxidase activity and ROS generation
are significantly higher in cerebral arteries compared with
systemic arteries (Miller et al., 2005, 2009). Moreover, this
is associated with greater expression levels of the Nox2- and
Nox4-NADPH oxidase isoforms (Miller et al., 2005, 2009). This
may reflect an important role for ROS-dependent signaling in
cerebral arteries. Indeed, ROS have been shown to be important
vasoactive molecules in cerebral arteries from healthy animals.
However, this potentially means that a smaller increase in ROS
levels is needed before antioxidant defense mechanisms are
overcome and oxidative stress ensues. The majority of studies
examining the effects of exogenously applied or endogenously
generated ROS infer that they are cerebral vasodilators during
health. For example, application of NADPH (substrate for the
NADPH oxidases) to cerebral vessels in vitro and in vivo elicits
vasodilation (Didion and Faraci, 2002; Park et al., 2004a; Miller
et al., 2005) that is dependent on hydrogen peroxide (Miller
et al., 2005). Moreover, NADPH-oxidase–derived ROS partly
mediate flow-dependent responses of rat cerebral arteries in vivo
(Paravicini et al., 2006). As such, it has been proposed that
ROS derived from NADPH oxidases may play an important
physiological role in regulating cerebral vascular tone and thus
potentially brain perfusion (Miller et al., 2006).
OXIDATIVE STRESS AND CEREBRAL
VASCULAR DYSFUNCTION
Oxidative stress is characterized by an imbalance between the
production and metabolism of oxidants in favor of a pro-oxidant
cellular environment. Excess oxidant levels can then overwhelm
the endogenous anti-oxidant systems. Oxidative stress can result
from overproduction of oxidants [in the form of ROS and reactive
nitrogen species (RNS)] by enzymes such as the NADPH oxidases
or from diminished anti-oxidant enzyme activity or anti-oxidant
levels (e.g., SODs, Gpx, and catalase).
Oxidative stress has major implications for cerebral vascular
function. Substantial evidence implicates oxidative stress as a key
contributor to the pathogenesis of many diseases that affect the
brain and its circulation. Indeed, as discussed in the following
sections, oxidative stress, driven primarily by the NADPH
oxidases may play an important role in the cerebral vascular
dysfunction associated with cerebral SVD risk factors and CAA.
It is well documented that oxidative stress can impair cerebral
vascular function via the disruption of endothelium-dependent
NO signaling (Girouard et al., 2006, 2007; Mayhan et al., 2008;
Miller et al., 2010). Indeed, the reaction of superoxide with
NO reduces NO bioavailability and thus diminishes its potent
vasodilator, anti-proliferative, and anti-inflammatory properties.
Importantly, this reaction also generates the RNS (ONOO−).
ONOO− is a powerful oxidant and can further accentuate
vascular dysfunction by causing damage to proteins and DNA,
and by impairing vascular responses to NO (Xie et al., 2005).
Although evidence points toward hydrogen peroxide being a
vasodilator ROS in the cerebral circulation, high concentrations
may lead to apoptosis of cerebral vascular cells (Li et al., 2003).
Moreover, this non-radical may impair vascular function through
its conversion into hydroxyl (OH.) in the metal-catalyzed Haber–
Weiss or Fenton reaction (Xie et al., 2005).
Another critically important consequence of reduced NO
bioavailability during disease is the loss of modulation of Rho
kinase activity. NO has been shown to modulate Rho kinase
activity in cerebral microvessels, such that inhibition of NO
synthase activity increases the influence of Rho kinase on vascular
tone (Didion et al., 2005). In addition, ROS may be able to directly
increase Rho kinase signaling (Jernigan et al., 2008; Aghajanian
et al., 2009). In turn, Rho kinase can influence both eNOS
expression (via effects on eNOS mRNA stability) and activity
(Laufs and Liao, 1998; Faraco et al., 2013). Thus, the loss of NO
during disease can start a viscous cycle, increased Rho kinase
activity leading to decreased NO synthase-derived NO, which
may further increase Rho kinase activity. Other mechanisms
of ROS-mediated vascular damage have been described during
non-amyloid and amyloid cerebral SVD disease states, including
activation of poly(ADP)-ribose polymerase (PARP) and transient
receptor potential melestatin-2 (TRPM2) channel activation. Our
current understanding of these mechanisms is discussed below.
DOES OXIDATIVE STRESS CONTRIBUTE
TO CEREBRAL VASCULAR
DYSFUNCTION IN CEREBRAL SVD?
Non-amyloid Cerebral SVD and its Risk
Factors
Sporadic SVD is difficult to model and study experimentally. As
such, research efforts to elucidate the arteriopathy of cerebral
SVD have largely focused on the use of experimental models
of its risk factors. Many of the key features of cerebral SVD
arteriopathy have been described in such models. However,
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there is a lack of evidence supporting a causal link between
these vascular abnormalities and, brain injury and cognitive
impairment. This latter point notwithstanding, experimental
models of cerebral SVD risk factors have revealed that oxidative
stress might be a common underlying mechanism responsible for
cerebral vascular dysfunction.
As mentioned, hypertension and aging are thought to
be the most important risk factors for cerebral SVD. The
harmful effects of hypertension on the cerebral vasculature have
been extensively studied and described. For example, some
of the key features of cerebral SVD have been described in
rodent models of hypertension including reductions in CBF,
impaired vasodilator capacity (e.g., NO-dependent responses,
neurovascular coupling, and autoregulation), inward remodeling,
and BBB disruption (Didion et al., 2000; Kim-Mitsuyama et al.,
2005; Faraci et al., 2006; Girouard et al., 2006, 2007; Henning
et al., 2010). Angiotensin II, the main effector peptide of the
renin-angiotensin system, appears to play an important role
in these vascular abnormalities (De Silva and Faraci, 2012).
Moreover, compelling evidence indicates that oxidative stress,
driven primarily by the NADPH oxidases, mediates many of the
deleterious effects of angiotensin II on the cerebral vasculature.
For example, angiotensin II acutely and chronically, increases
superoxide production by Nox2-NADPH oxidase in rodent
cerebral vessels (Girouard et al., 2006, 2007; De Silva et al.,
2009; Jackman et al., 2009b; De Silva and Faraci, 2012). Also,
functional impairments of mouse cerebral arterioles following
angiotensin II treatment are prevented by co-treatment with
either the ROS scavenger MnTBAP or the Nox2-NADPH oxidase
peptide inhibitor gp91ds-tat (Girouard et al., 2006). Furthermore,
studies of mice genetically deficient of Nox2 also suggest a
role for Nox2-NAPDH oxidase in the functional abnormalities
caused by angiotensin II (Girouard and Iadecola, 2006; Girouard
et al., 2006, 2007; Chrissobolis et al., 2012). More recently,
studies have shown that angiotensin II can also activate and
increase superoxide production in cerebral vessels by activating
Nox1-NADPH oxidase (Jackman et al., 2009a). However, this
isoform appears to only play a minor role in the vascular
abnormalities caused by angiotensin II (Chrissobolis et al.,
2012).
Several studies have shown that oxidative stress and
the NADPH oxidases also mediate the deleterious effects
of hypertension/angiotensin II on the microcirculation.
For example, scavenging of superoxide by tempol or the
NADPH oxidase inhibitor apocynin reduce BBB disruption
in spontaneously hypertensive stroke prone rats (SHRSP) rats
treated with angiotensin II (Kim-Mitsuyama et al., 2005).
Similarly, tempol attenuates leukocyte/endothelial interactions
and BBB disruption in mice treated with angiotensin II (Zhang
et al., 2010). BBB disruption, tight junction protein loss, and
oxidative stress have also been reported in other models of
hypertension such as Dahl salt-sensitive rats (Kalani et al.,
2016). At present, the downstream mechanisms responsible for
the ROS-mediated BBB dysfunction have not been identified.
However, studies of cerebral ischemia and reperfusion implicate
Rho kinase activation as a key mechanism underpinning
ROS-induced BBB disruption (Kahles et al., 2007). The
potential involvement of Rho kinase in BBB dysfunction during
hypertension and cerebral SVD warrants further investigation.
Oxidative stress has been shown to play a critical role
in mediating changes to cerebral vascular structure. Changes
in arteriolar structure have profound effects on CBF. Inward
remodeling results in a reorganization of the vessel wall such
that there is a reduction in lumen diameter that does not result
from changes in vessel reactivity or mechanics (Faraci, 2011).
Also, inward remodeling reduces lumen diameter even when
vessels are fully dilated (Baumbach and Heistad, 1989; Baumbach
et al., 2003). Nox2-deficient mice are protected from the
cerebral vascular hypertrophy and inward remodeling induced
by angiotensin II (Chan and Baumbach, 2013a,b), implicating a
role for Nox2-NADPH oxidase-derived ROS in these structural
abnormalities. The precise signaling cascade through which ROS
mediates these changes is yet to be elucidated. Recent studies
indicate that a signaling cascade involving caveolin-1-containing
microdomains, epidermal growth factor receptor (EGFR), c-Src
and Akt is required for the hypertrophic response to angiotensin
II in cerebral arterioles (Chan et al., 2015; Umesalma et al.,
2016). Moreover, increased expression and activation of matrix
metalloproteinase-9 (MMP-9) appears to be crucial for the
cerebral vascular inward remodeling (Umesalma et al., 2016).
Whether ROS activate these signaling cascades to mediate
cerebral vascular remodeling remains to be tested.
Another important structural change that is associated with
cerebral SVD is vessel rarefaction (particularly in the white
matter; Brown et al., 2007), which is the loss of collateral
vessel number and a decrease in the diameter of remaining
vessels (De Silva and Faraci, in press). Rarefaction was recently
shown to occur in cerebral pial arterioles and capillaries
during hypertension, aging, diabetes, hypercholesterolemia, and
metabolic syndrome (Faber et al., 2011; Moore et al., 2015).
Furthermore, the impact of hypertension on collateral vessels
was worsened by the severity and duration of the hypertension
(Moore et al., 2015). While direct evidence for a role for
ROS and NADPH oxidase is currently lacking, the fact that
oxidative stress has been shown to be present in hypertension,
albeit with different end points, raises the possibility that
ROS and NADPH oxidases may play a role in rarefaction.
Consistent with this, chronic blockade of angiotensin II type
1 receptors (AT1) and angiotensin-converting enzyme (ACE)
reverses brain functional capillary rarefaction and lowers brain
oxidative stress in diabetic hypertensive rats (Estato et al.,
2013). Recent evidence highlights the importance of pericytes
in regulation microcirculation, brain capillary perfusion, cerebral
vascular responses, and BBB integrity. Indeed, pericyte deficient
mice display marked reductions in microcirculation and BBB
disruption (Bell et al., 2010). To the best of our knowledge, it is
unclear whether hypertension influences pericyte function and
number, and whether oxidative stress contributes to any such
effect. However, given pericytes express Nox-NADPH oxidases
and generate ROS in response to angiotensin II (Kuroda et al.,
2014), it is conceivable that oxidative stress may have deleterious
effects on pericytes during hypertension.
Similar to hypertension, it is well documented that diverse
vascular changes occur with aging. In the human and rodent
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cerebral circulation, aging produces functional abnormalities
including reduced resting CBF and impaired endothelium-NO-
dependent responses and neurovascular coupling (Hatake et al.,
1990; Mayhan et al., 1990, 2008; Park et al., 2007; Modrick
et al., 2009, 2012; Pena Silva et al., 2012). Also, studies of aged
rodents have shown that cerebral arterioles undergo structural
changes such as atrophy, reduced distensibility, and a reduction
in elastin and smooth muscle (Hajdu et al., 1990). Similarly, in
humans, aging increases wall thickness and reduces distensibility
of large cerebral arteries such as the basilar and vertebral
arteries (Nagasawa et al., 1979). Studies suggest a major role
for oxidative stress and the NADPH oxidases in age-related
cerebral vascular abnormalities. For example, acute scavenging
of superoxide by tempol or MnTBAP improves NO-dependent
vasodilator responses and neurovascular coupling in aged mice
(Mayhan et al., 2008; Modrick et al., 2009). Inhibition of
NADPH oxidases with apocynin, diphenyleniodonium (DPI) or
gp91ds-tat, also improves cerebral vascular function in aged
mice (Mayhan et al., 2008). Also, age-related cerebral vascular
abnormalities are not found in Nox2-deficient mice (Park et al.,
2007). The renin-angiotensin system may contribute to the
vascular changes in aging. Indeed, levels of angiotensin II,
ACE, and AT1 receptors are increased in peripheral vessels
of aged monkeys and old humans (Wang et al., 2003, 2007).
Moreover, genetic deletion of AT1 attenuates cerebral vascular
dysfunction in aged mice (Modrick et al., 2009). In addition to
oxidative inactivation of NO, studies have shown that activation
of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
by ROS contributes to cerebrovascular endothelial dysfunction
during aging (Modrick et al., 2009). To the best of our knowledge,
no study has examined whether oxidative stress and the NADPH
oxidases contribute to age-related structural abnormalities of
cerebral vessels. Moreover, it is unknown whether oxidative
stress contributes to age-related rarefaction of arterioles and
capillaries, and pericyte loss (Bell et al., 2010; Faber et al.,
2011).
Studies of experimental models of other cerebral SVD risk
factors such as hypercholesterolemia (Kitayama et al., 2007;
Miller et al., 2010), diabetes (Mayhan et al., 1991, 2006; Didion
et al., 2005, 2007; Arrick et al., 2008; Ergul et al., 2009),
obesity (Lynch et al., 2013), and homocysteinaemia (Dayal et al.,
2004, 2005; Devlin et al., 2004), indicate that all are associated
with functional abnormalities and oxidative stress. For example,
genetic deletion of Nox2 in hypercholesterolemic apolipoprotein
E-deficient mice prevents elevations in ROS production and
impaired vasodilator capacity of cerebral vessels (Miller et al.,
2010). Similarly, Nox2-deficient mice are protected against
obesity-induced dysfunction of cerebral arterioles (Lynch et al.,
2013). Moreover, activation of PARP (Arrick et al., 2007), Rho
kinase (Didion et al., 2005), and AT1R (Arrick et al., 2008)
have also been shown to be involved in cerebral microvascular
dysfunction. Thus, as in models of hypertension and aging, the
generation of ROS by NADPH oxidases and the activation of
key signaling pathways such as PARP and Rho kinase might be a
common underlying mechanism of cerebral vascular dysfunction
caused by many of the known risk factors for cerebral SVD.
Amyloid Cerebral SVD
The mechanisms underlying CAA-induced vascular
abnormalities remain to be fully elucidated. In the scenario
where Aβ deposition occurs, it could involve alterations in
vasomotor apparatus, including the loss of smooth muscle
cells due to the toxic properties of Aβ (Ruzali et al., 2013).
Moreover, Aβ may also present a mechanical obstacle to
vessel dilatation, or by interfering with intracellular signaling
pathways (Christie et al., 2001). Notably, oxidative stress
is evident in cerebral vessels of aged APP mice with CAA
(Hamel et al., 2008; Park et al., 2008, 2014b). Similarly,
Garcia-Alloza et al. (2009) found a strong correlation between
CAA-positive cerebral vessels and oxidative stress in two APP
transgenic mouse models that develop CAA (APPswe/PS1dE9
and Tg2576). In addition, emerging evidence suggests that
oxidative stress may play an important role in mediating the
deleterious effects of Aβ/CAA on the cerebral vasculature.
For example, a recent study by Han et al. (2015) showed that
chronic treatment with the ROS scavenger tempol reduces
oxidative stress and improves vasodilator responses of cerebral
arterioles in aged APP transgenic mice with CAA. Also, they
provided evidence that oxidative stress may also contribute to
CAA-related microhemorrhage (Han et al., 2015). Park et al.
(2014a) also demonstrated that oxidative stress contributes to
vascular dysfunction in APP transgenic mice, however, they
also showed that with advancing age, structural alterations
(e.g., smooth muscle fragmentation and pericyte loss) also
play a role. Genetic deletion or inhibition of Nox2 improves
the functioning of cerebral vessels of aged APP mice, which
typically exhibit CAA (Park et al., 2007, 2008). Similarly, the
purported NADPH oxidase inhibitor apocynin, or tempol,
reduce oxidative stress and cerebral vascular abnormalities
in aged APP mice with CAA (Han et al., 2015). Thus, the
NADPH oxidases, in particular the Nox2 isoform, might be
a key driver of oxidative stress-induced vascular dysfunction
in CAA, however, there is a paucity of studies examining the
potential roles of other NADPH oxidase isoforms and/or other
ROS enzymatic sources. Although the precise mechanism
through which Aβ activates the NADPH oxidases remains to
be fully determined, recent evidence implicates a role for CD36,
which is an important innate immunity receptor that binds
Aβ and is expressed on endothelial cells (Park et al., 2011,
2013).
As discussed, it is well established that superoxide can impair
cerebral vascular function by inactivating vasoprotective NO.
Moreover, it is well documented that the reaction between
superoxide and NO also generates ONOO−. In addition to
oxidative stress, studies have also found evidence that nitrosative
damage may also contribute to the vascular abnormalities in
CAA (Park et al., 2014b). Moreover, the molecular mechanism
by which ONOO− causes cerebral vascular dysfunction in
response to Aβ has been described. Specifically, Park et al.
(2014b) showed that Aβ-induced nitrosative stress caused DNA
damage, resulting in PARP activation and ultimately an increase
in intracellular ADP ribose in cerebral arterioles. This in
turn activates TRPM2 channels, leading to a large increase
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in intracellular calcium and ultimately endothelial dysfunction.
Notably, evidence suggests that ROS may also be able to
directly activate TRPM2 channels, bypassing the need for PARP
activation (Hecquet et al., 2008). As discussed above, PARP has
been identified as a downstream target of ROS and mediator of
endothelial dysfunction during hypertension, diabetes, and aging.
Thus, both amyloid and non-amyloid forms of cerebral SVD
appear to converge on similar molecular pathways. Therefore,
targeting these pathways would potentially be beneficial in many
forms of cerebral SVD.
In the case of soluble Aβ, evidence also implicates oxidative
and nitrosative stress as a key mechanism. Cerebral arterioles
of young APP transgenic mice, which have increased levels of
endogenous Aβ but no CAA, exhibit signs of oxidative stress
and nitrosative damage (Park et al., 2004b, 2008). Moreover,
genetic overexpression of SOD or treatment with ROS scavengers
improves cerebral vascular function in these mice (Iadecola et al.,
1999; Nicolakakis et al., 2008; Park et al., 2008). Several lines of
evidence indicate that a key mechanism through which soluble
Aβ produces oxidative stress and vascular dysfunction involves
the activation of Nox2-NADPH oxidase (Park et al., 2005; Hamel
et al., 2008). However, future research is needed to investigate
whether other NADPH oxidase isoforms also contribute.
Our understanding of the mechanisms underpinning the
deleterious effects of Aβ on the microcirculation lags behind
that of large vessels and arterioles. Some evidence does,
however, support the notion that oxidative stress is common
contributing mechanism throughout the cerebral vascular tree.
For example, Aβ increases Nox-dependent H2O2 formation by
human microvascular endothelial cells (in vitro BBB model)
and decreases mRNA levels of tight junctions proteins (Carrano
et al., 2011). Genetic deletion of CD36 in APP transgenic
mice attenuates damage to smooth muscle cells and pericytes,
increases pericyte numbers and improves morphology (Park
et al., 2013). Thus, ROS may contribute to pericyte loss
in CAA, which in turn is likely to further accentuate BBB
disruption. Consistent with this, the aforementioned study
found that expression of the tight junction protein ZO-1 is
preserved in CD36 deficient APP mice (Park et al., 2013).
Interestingly, post mortem studies have shown that the
expression of tight junction proteins is diminished in Aβ-laden
capillaries, which are surrounded by Nox2-positive activated
microglia (Carrano et al., 2011, 2012). Thus, microglial Nox2-
NADPH oxidase may be an important source of ROS in the
microcirculation.
The role of oxidative stress in the process of Aβ deposition
in the vascular wall is less clear. Heterozygous knockdown
of SOD2 in APP transgenic mice increases the deposition
of Aβ in the cerebral vasculature (Esposito et al., 2006),
suggesting a role for mitochondrial ROS in vascular Aβ burden.
A more recent study showed that tempol or apocynin markedly
reduce CAA formation in aged APP mice (Han et al., 2015),
implicating ROS and potentially the NADPH oxidases in vascular
amyloid pathogenesis. Several studies have, however, shown no
beneficial effect of ‘anti-oxidant’ strategies (e.g., the non-specific
ROS scavengers, phenyl-N-ter-butyl nitrone; curcumin; and
pomegranate juice) on CAA formation and burden (Hartman
et al., 2006; Garcia-Alloza et al., 2011), which may relate to issues
of potency and specificity of these ROS scavengers.
CONTRIBUTION OF OXIDATIVE STRESS
IN CEREBRAL SVD-RELATED BRAIN
INJURY AND COGNITIVE IMPAIRMENT
Various experimental models have been employed to study the
brain lesions and cognitive impairment that typically manifest in
sporadic cerebral SVD. These include chronically hypertensive
animals (e.g., SHRSP rats), chronic hypoperfusion models (e.g.,
carotid occlusion or stenosis models), and models of focal or
global ischemia induced by surgical or pharmacological occlusion
of a cerebral artery [e.g., monofilament or endothelin-1 (ET-1)
models]. However, unfortunately no model exhibits all of the
key features of human cerebral SVD (Hainsworth and Markus,
2008). This latter point notwithstanding, compelling evidence
from studies using these animal models implicate oxidative stress
as a key mediator of ischemic brain injury (Dong et al., 2011;
Ueno et al., 2015). Moreover, evidence suggests that the NADPH
oxidases, expressed in various cell types in the brain, are major
sources of this ROS-mediated ischemic injury.
Walder et al. (1997) were the first to implicate Nox2-NADPH
oxidase as a key mediator of ischemic brain injury by showing
that Nox2-deficient mice have less brain injury after focal
ischemia. Numerous subsequent studies have confirmed this
finding in focal and global models (Chen et al., 2009; Jackman
et al., 2009b; Brait et al., 2010; De Silva et al., 2011; Yoshioka
et al., 2011), and have also shown a role for Nox2-NADPH
oxidase in ischemia-induced BBB disruption, and dysfunction
of larger pial arteries upstream of the BBB (Kahles et al., 2007;
De Silva et al., 2011). Studies using mice deficient of Nox4
also suggest a role for Nox4-NADPH oxidase in ischemic brain
injury. Indeed, Nox4 deficient mice develop less brain injury after
focal ischemia as a result of reduced oxidative stress, neuronal
apoptosis, and BBB disruption (Kleinschnitz et al., 2010). The
role of Nox1-NADPH oxidase is less clear. Some studies have
found no protection in Nox1-deficient mice after focal ischemia
(Jackman et al., 2009a; Kleinschnitz et al., 2010), whereas others
have shown that knockdown of Nox1 (Choi et al., 2014, 2015)
reduces neuronal cell death in rat models of focal or chronic
hypoperfusion.
Pharmacological evidence also implicates the NADPH
oxidases in ischemic-related brain injury. Indeed, numerous
studies have shown that apocynin provides neuroprotection in
focal, global and chronic hypoperfusion models (Tang et al.,
2008; Chen et al., 2009; Jackman et al., 2009b; Choi et al., 2014;
Zhang et al., 2015), protects against BBB disruption (Kahles et al.,
2007; Tang et al., 2008) and hemorrhage (Tang et al., 2008), and
attenuates enhanced ROS production and neuronal apoptosis in
stroke-prone spontaneously hypertensive rats (Yamamoto et al.,
2008). Moreover, some studies using Nox2 deficient mice imply
that the protection afforded by apocynin involves inhibition of
Nox2-NADPH oxidase (Kahles et al., 2007; Chen et al., 2009;
Jackman et al., 2009b). Notably, two studies have shown that
apocynin has a narrow therapeutic window (Tang et al., 2008;
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Jackman et al., 2009b) and thus may represent a challenge for
therapeutic development. Recently, intrathecal administration
of the NADPH oxidase inhibitor VAS2870 was also shown to
reduce brain injury after focal ischemia (Kleinschnitz et al.,
2010). Moreover, the administration of this inhibitor to Nox4-
deficient mice (who are protected themselves) conferred no
further benefit, implying that VAS2870 protects against ischemia
via inhibition of Nox4-NADPH oxidase (Kleinschnitz et al.,
2010).
Experimental studies using natural anti-oxidants also
implicate oxidative stress as a contributor in the cognitive
impairment associated with cerebral SVD. For example,
the polyphenol anti-oxidant, catechin (from green tea),
improves learning and memory in rats after chronic cerebral
hypoperfusion, an effect that was associated reduced lipid
peroxidation and oxidative DNA damage (Xu et al., 2010).
L-carnitine also improves learning and memory in rats after
chronic cerebral hypoperfusion (Ueno et al., 2015). Moreover,
these improvements were associated with reduced lipid
peroxidation and oxidative DNA damage, as well as enhanced
oligodendrocyte marker expression and myelin sheath thickness
indicative of an improvement in white matter lesions (Ueno
et al., 2015). Another study found that high doses of Vitamin
E improve learning and memory, and reduce markers of
oxidative stress (malondialdehyde levels) and cellular injury
(lactate dehydrogenase) in stroke-prone hypertensive rats
(Murad et al., 2014). As with ischemic-related injury, the
NADPH oxidases might contribute to oxidative stress-induced
cognitive impairment. For example, apocynin reduces oxidative
stress and improves learning and memory in rat or mouse
models of chronic hypoperfusion (Shen et al., 2011; Choi
et al., 2014; Toyama et al., 2014). Moreover, inhibition of
Rac1, which is a small GTPase essential for the assembly and
activation of the NADPH oxidases, reduces oxidative stress and
improves memory in rats after induction of transient chronic
hypoperfusion (Raz et al., 2010). Lastly, Choi et al. (2014) showed
that knockdown of Nox1 reduces ROS generation, oxidative
DNA damage, and cognitive impairment, implicating a role for
the Nox1-NADPH oxidase isoform.
PHARMACOLOGICAL STRATEGIES FOR
CEREBRAL SVD
Despite evidence that it has devastating effects on the brain,
there are at present no specific pharmacological strategies to
prevent or treat cerebral SVD. Given there are a number of well-
known risk factors for cerebral SVD one would be predict that
prevention (primary and secondary) is a realistic possibility. The
benefits for lowering blood pressure with anti-hypertensives are
apparent in reducing both first and recurrent stroke. Indeed,
in the Systolic Hypertension in the Elderly Program (SHEP),
lowering blood pressure with anti-hypertensives reduced the
incidence of both hemorrhagic and ischemic stroke, including
lacunar (Perry et al., 2000). Also, anti-hypertensive therapy is
beneficial for the secondary prevention of subcortical strokes
in patients with lacunar infarction (Benavente et al., 2012),
and reduces intracerebral hemorrhage (Benavente et al., 2013).
Whether anti-hypertensives slow the progression of WMH is less
clear. For example, the Perindopril Protection against Recurrent
Stroke Study showed that an intensive blood pressure-lowering
regime might slow the progression of WMH progression in
stroke patients (Dufouil et al., 2005), whereas other trials have
noted little or no effect (Bath and Wardlaw, 2015).
Several studies have also demonstrated that statins reduce
both first and recurrent stroke. Small clinical studies have shown
that statin therapy increases CBF in patients with leukoaraiosis
(Ebinger et al., 2012), and improve cerebral vascular function
and in patients with lacunar stroke (Pretnar-Oblak et al.,
2006). Furthermore, although large clinical trials of statins
specifically after lacunar stroke are lacking, the Stroke Prevention
by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
showed that statin therapy reduces recurrent stroke to a similar
degree in small vessel and large artery stroke, but there was a
modest but significant increase in hemorrhagic stroke (Amarenco
et al., 2009). In contrast, a more recent study found no effect of
statin treatment on either incident lacunes or microbleeds (Xiong
et al., 2014). Data on the effects of statin treatment on WMH
are controversial. For example, the Regression of Cerebral Artery
Stenosis (ROCAS) study reported reduced WMH progression
(Mok et al., 2009). Similarly, statin use in participants of the
VITAmins To Prevent Stroke MRI substudy was found to reduce
WMH and decline in executive function (Xiong et al., 2014),
whereas no effect was found in a substudy the Prospective Study
of Pravastatin in Elderly at Risk (PROSPER; ten Dam et al., 2005).
As with other stroke subtypes, thrombolysis (i.e., using rt-PA)
is commonly used for the treatment of patients with cerebral
SVD. However, unlike large vessel or cardioembolic stroke, clot
formation in lacunar infarction is not considered to be an
important mechanism. Nevertheless, some studies have shown
that rt-PA improves neurological outcomes of cerebral SVD
patients with lacunar infarcts (Mok and Kim, 2015). One concern
regarding the use of rt-PA is the possibility of increase risk
of hemorrhage in those patients with co-existing WMH or
microbleeds (Mok and Kim, 2015). There are similar concerns
with the use of anti-platelet drugs for secondary prevention in
patients with cerebral SVD (Mok and Kim, 2015).
Potential prophylactic and treatment strategies for
arteriopathy in cerebral SVD might include those that target
the endothelium of large and small cerebral vessels, as well as
the endothelium of the BBB (Bath and Wardlaw, 2015; Poggesi
et al., 2015). Given vasoprotective NO bioavailability might be
impaired, NO donors may be useful in rescuing the functioning
(and potentially the structural abnormalities) of the cerebral
vasculature. The clinical efficacy of traditional NO donors (e.g.,
glyceryl trinitrate) is, however, limited by their susceptibility to
tolerance development, decreased effectiveness under oxidative
stress and cytotoxic effects (Bullen et al., 2011). Novel NO agents
such as nitroxyl (HNO) donors and NO-independent sGC
activators (e.g., BAY 58-2667) are proposed to have advantages
over these traditional donors (Evgenov et al., 2006; Bullen
et al., 2011; Miller et al., 2013). For example, similar to NO,
HNO has potent vasodilator properties, but is resistant to both
scavenging by superoxide and tolerance development (Bullen
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et al., 2011; Miller et al., 2013). In addition, it can suppress the
activity of Nox2-NADPH oxidase in cerebral vessels and thus
may also be effective in ameliorating oxidative stress (Miller
et al., 2013). Other potential interventions for improving artery
function could include prostacyclin mimics, PPARγ activators,
anti-inflammatory agents, phosphodiesterase-5 inhibitors, and
Rho-kinase inhibitors (Bath and Wardlaw, 2015).
TARGETING OXIDATIVE STRESS AS A
THERAPEUTIC STRATEGY?
As discussed in this review, compelling evidence indicates
that oxidative stress might be an important contributor to
arteriopathy in cerebral SVD (non-amyloid and amyloid), and
also the brain injury and cognitive impairment that typically
accompanies it. Targeting oxidative stress as a strategy for the
treatment of vascular-related diseases has been proposed and
discussed by countless researchers over the past decade or
so. However, the potential application of this strategy for the
prevention and treatment of cerebral SVD is relatively new.
It is important, however, to remember that ROS have
important physiological roles including the normal regulation
of cerebral vascular function (see Reactive oxygen species and
cerebral vascular function). Thus approaches to ameliorate
oxidative stress would need to be balanced to ensure that these
important physiological roles remain intact.
Conventional Anti-Oxidants
There has been much debate about the usefulness of bolstering
levels of anti-oxidants to ameliorate oxidative stress in vascular
disease per se. Administration of anti-oxidants such as Vitamins
C and E has shown to be beneficial for vascular function in a
number of experimental and small clinical trials (Drummond
et al., 2011). A small clinical trial showed that Vitamin E
supplementation attenuates the development of white matter
lesions (Gopalan et al., 2014). Moreover, as discussed, natural
anti-oxidants such as Vitamin E and L-carnitine have shown to
be beneficial for cognitive impairments found in rodent models
of cerebral SVD (Murad et al., 2014; Ueno et al., 2015). However,
disappointingly, results of large clinical trials of anti-oxidant
supplementation in vascular disease and stroke have largely
failed to show any benefit. For example, the Heart Protection
Study found no effect of Vitamin C, Vitamin E and β-carotene
supplementation on the incidence of vascular events (including
stroke) in 20,500 high-risk individuals (Heart Protection Study
Collaborative, 2002).
The reasons for the ‘failure’ of such anti-oxidant strategies may
relate to the use of suboptimal doses of the vitamins. It is now
recognized that supra-physiological concentrations of Vitamins
C and E would be required to compete with the reaction of
superoxide and NO (Drummond et al., 2011). Also, although the
treatment regimes were effective in increasing plasma levels of
anti-oxidants, whether this translates to increased levels in the
vasculature was not examined. Even if sufficient levels of anti-
oxidants were achieved in vascular cells, the anti-oxidants might
in fact exert pro-oxidant effects as a result of their conversion to
radical species following their reaction with superoxide (Witting
et al., 1997, 1999). Either way, the current consensus is that the
‘traditional’ anti-oxidant approach may not be the best strategy
for combatting oxidative stress in cerebral SVD (Drummond
et al., 2011).
Synthetic ROS Scavengers
Enhancing the metabolism of superoxide by SOD could be
an effective way to ameliorate the impact of this ROS on
vascular function. This could be achieved by using native SOD
that is modified to include a polyethylene glycol group, which
improves its ability to enter cells and stability. The ROS scavenger
tempol is cell-permeable and has been used in experimental
studies examining the role of oxidative stress in the arteriopathy
associated with cerebral SVD risk factors (Kim-Mitsuyama et al.,
2005; Mayhan et al., 2008; Modrick et al., 2009; Zhang et al., 2010;
Han et al., 2015). Small cell-permeable molecules that mimic
native SOD have been developed including, MnTBAP, which
have shown some potential therapeutic benefit in experimental
studies of cerebral SVD risk factors (Girouard et al., 2006;
Mayhan et al., 2008). Further studies are of course necessary
to fully establish their real therapeutic efficacy. The therapeutic
potential of ebselen (Gpx mimetic, ONOO− scavenger and Nox
inhibitor), edavarone (O2− scavenger), and the radical trapping
agent disufenton sodium (NXY-059), for the treatment of stroke
have been tested. Some clinical benefit has been reported for
both ebselen and edaravone, however, no benefit has been
demonstrated with NXY-059 (Allen and Bayraktutan, 2009).
Would Inhibition of the NADPH Oxidases
be an Effective Strategy?
Evidence supports a role for NADPH oxidase-derived ROS
in both arteriopathy and brain damage caused by cerebral
SVD and its risk factors. As such, the use of pharmacological
inhibitors of the NADPH oxidases may be an effective strategy.
Moreover, given research thus far point toward the Nox2-
NADPH oxidase isoform as a major contributor, selectively
targeting this isoform may be the most effective approach. It is
important to remember, however, that Nox2-NADPH oxidase
is also expressed in phagocytic immune cells and plays a
crucial role in immunological responses. Thus, long-term therapy
with inhibitors, which would be necessary for the prevention
and treatment of cerebral SVD, is likely to impair immune
function and thus could carry significant side effects such as
immunosuppression. Over the past decade, numerous inhibitors
of the NADPH oxidases have been developed and are well cited
in the literature. The mechanism(s) of action and therapeutic
potential of many of these inhibitors have been comprehensively
reviewed (Miller et al., 2006; Selemidis et al., 2008; Jaquet et al.,
2009; Drummond et al., 2011; Altenhofer et al., 2015; Bedard
et al., 2015), and therefore will only be reviewed briefly here.
Clinically used Drugs That Target NADPH Oxidases
and Oxidative Stress
As mentioned, the control of vascular risk factors (e.g.,
hypertension, hypercholesterolemia, diabetes) is an important
primary and secondary preventative strategy for cerebral SVD
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and associated brain injury/dysfunction. Notably, three of the
most effective and frequently prescribed classes of drugs for the
treatment of vascular risk factors have been shown to inhibit
NADPH oxidases, and thus are likely to mediate their beneficial
actions, in part, by reducing oxidative stress. These include the
ACE inhibitors, AT1 antagonists and the statins. As discussed,
angiotensin II acutely and chronically increases the activity of
the NADPH oxidases. ACE inhibitors decrease the conversion
of angiotensin I to angiotensin II, whereas angiotensin receptor
antagonists block receptor mediated effects of angiotensin II.
Thus, both of these therapies are likely to reduce ROS levels under
conditions of oxidative stress by preventing the activation of the
NADPH oxidases by angiotensin II.
Statins are primarily used therapeutically to lower LDL-
cholesterol levels, however, it is well documented that statins
exert additional cardiovascular benefits. Indeed, statins have been
reported to exert direct protective effects on the vasculature
by improving endothelial-derived NO bioavailability and thus
endothelial function (Erdos et al., 2006; Tanaka et al., 2007;
Pretnar-Oblak et al., 2008; Tong et al., 2009). For example, short-
term statin treatment improves vasomotor reserve capacity in
healthy adults (Sander et al., 2005). Also, statin therapy improves
cerebral endothelial function in patients with lacunar stroke,
hypertension, and hypercholesterolemia (Pretnar-Oblak et al.,
2006, 2008). Moreover, the beneficial effects of statins on CBF and
brain injury after cerebral ischemia are dependent on endothelial
NO synthase (Endres et al., 1998; Laufs et al., 2000). Evidence
suggests that statins augment NO bioavailability, at least in part,
via their inhibitory action on RhoA, which negatively regulates
eNOS expression (Budzyn et al., 2006). In addition, statins
prevent the activation of Rac1, a small G-protein required for
NADPH oxidase activation. Consistent with this, statins inhibit
cerebral vascular superoxide production in experimental models
of diabetes (Erdos et al., 2006), protect against cerebral ischemia,
in part, by attenuating oxidative stress (Hayashi et al., 2005), and
rescue Aβ-mediated cerebral vascular deficits and oxidative stress
in aged APP mice (Tong et al., 2009). Thus, statins may improve
cerebral endothelial function by enhancing NO bioavailability
and by decreasing oxidative stress.
Historical NADPH Oxidase Inhibitors
Diphenyleniodonium and apocynin are the most frequently
used NADPH oxidase inhibitors. Indeed, both have been
used to demonstrate a role for the NADPH oxidases in the
arteriopathy associated with cerebral SVD risk factors and CAA,
as well as ischemic brain injury and cognitive impairment.
Unfortunately, however, both have non-specific effects that will
limit their clinical usefulness. For example, the flavin antagonist,
TABLE 1 | Novel NADPH oxidase inhibitors: proposed isoform selectivity, mechanism of action, and off-target effects.
Compound Isoform selectivity Mechanism of action Off-target effects Reference
Gp91ds-tat Nox2 oxidase Inhibits assembly of active Nox2
complex, by preventing the
interaction of p47phox with Nox2
catalytic subunit.
None reported Rey et al., 2001; Csanyi
et al., 2011
VAS2870 Nox2, Nox4, Nox5 oxidases Inhibits assembly of active Nox2
complex but not via interfering with
the translocation of p47phox.
Actions on Nox4 and Nox5
undefined.
Thioalkylates cysteine
residues
ten Freyhaus et al., 2006;
Kleinschnitz et al., 2010;
Sun et al., 2012
Pyrazolopyridine derivative
(e.g., GKT136901 and
GKT137831)
Nox1, Nox4, Nox5 oxidases Not defined. May competitively
inhibit the substrate NADPH.
None reported Laleu et al., 2010; Gaggini
et al., 2011
S17834 Not defined, although is likely to
inhibit at least Nox2, and Nox4
oxidases
Not defined. Activates AMPK Cayatte et al., 2001; Zang
et al., 2006
Ebselen and analogs (e.g.,
JM-77b)
Nox1, Nox2, and Nox5
oxidases
Inhibits interaction of p47phox with
the membrane bound subunit
p22phox
Gpx mimetic; ONOO−
scavenger; Moderate
eNOS inhibitor
Muller et al., 1984;
Zembowicz et al., 1993;
Briviba et al., 1996; Bedard
and Jaquet, 2012
Fulvene-5 Nox2, Nox4 oxidases Not defined Not determined Bhandarkar et al., 2009
Triphenylmethane derivatives
(e.g., Brilliant green, Gentian
violet),
Nox2, Nox4 oxidases Not defined. May interfere with
extracellular Nox domains. Similar
structure to the flavin antagonist,
DPI.
Not determined Perry et al., 2006; Munson
et al., 2012
Grindelic acid Nox4 oxidase Not defined May inhibit other
flavoproteins
Kofler et al., 2013
ML171 (2-acetylphenothiazine) Nox1 > Nox2, and Nox4
oxidases
Not defined May inhibit serotonin
and adrenergic
receptors
Gianni et al., 2010
AMPK, adenosine monophosphate-activated protein kinase (AMPK); DPI, diphenyleneiodonium; eNOS, endothelial nitric oxide synthase; Gpx, glutathione peroxidase;
ONOO−, peroxynitritre.
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FIGURE 1 | Compelling experimental evidence suggests that oxidative stress underlies some aspects of cerebral vascular dysfunction associated
with known risk factors for non-amyloid cerebral small vessel disease (SVD), and contributes to the deleterious actions of soluble and deposited
amyloid-beta in the setting of cerebral amyloid angiopathy (CAA). The NADPH oxidases appear to be a major driver of this oxidative stress, however, future
research is needed to elucidate the potential contributes of other enzymes. Various experimental models have been employed to study the cerebral vascular lesions
and cognitive impairment that typically manifest in cerebral SVD. Oxidative stress and the NADPH oxidases are once again implicated. Despite evidence of its
devastating effects on the brain, there are at currently no specific pharmacological strategies to prevent or treat cerebral SVD. Modifying risk factors with drugs
already in the clinic (e.g., ACE inhibitors, angiotensin II receptor blockers) seems like a logical approach. Moreover, agents that target the endothelium (i.e., increasing
nitric oxide bioavailability) may be useful in rescuing the functioning of the cerebral vasculature. Lastly, strategies to combat oxidative stress (e.g., NADPH oxidase
inhibitors) may also be a novel strategy.
DPI inhibits all flavin-containing enzymes including the NO
synthases (Stuehr et al., 1991) and cytochrome P450 enzymes
(O’Donnell et al., 1993). Apocynin on the other hand can
act as a pro-oxidant under certain conditions and inhibits the
formation of prostanoids (Stolk et al., 1994; Vejrazka et al.,
2005). Other less commonly used ‘historical’ NAPDH oxidase
inhibitors include tosylphenylalanyl chloromethane (TPCK) and
aminoethyl benzenesulfonyl fluoride (AEBSF), which inhibit by
interfering with the translocation of p47phox and/or p67phox to
the Nox catalytic domain. However, both have a number of off-
target effects including anti-coagulation (McCarthy and Macey,
1996).
Novel Inhibitors
Our growing understanding on the biochemical properties of
the NADPH oxidases, as well as how they are activated, has
facilitated the identification and development of several novel
small-molecule NADPH oxidase inhibitors. The first of these was
the peptide gp91ds-tat, which was designed to inhibit the Nox2-
NADPH oxidase isoform. It comprises of a conserved sequence of
Nox2/gp91phox linked to a 9-amino acid peptide from the HIV
coat, which allows the peptide penetrate cells (Rey et al., 2001).
Gp91ds-tat has proven to be an invaluable pharmacological tool
in studies investigating the role of Nox2-NADPH oxidase in
disease. However, being a peptide it is unlikely to have efficacy
if administered orally, and thus its therapeutic potential is very
limited.
A number of promising NADPH oxidase inhibitors are
emerging through high-throughput screening of compound
libraries (Altenhofer et al., 2015; Table 1). For example, Triazolo
pyrimidines (e.g., VAS2870 and VAS3947) were developed in
a screening approach for Nox2-NADPH oxidase inhibitors
(Stielow et al., 2006; ten Freyhaus et al., 2006). However, it is
now apparent that it may also inhibit the activity of Nox4- and
Nox5-NADPH oxidases (Kleinschnitz et al., 2010), and thus is
not isoform specific. Unfortunately, VAS2870 has poor solubility
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and off-target effects (e.g., modulating the thiol redox state;
Sun et al., 2012), which limits its use in vivo. Pyrazolopyridine
derivative (e.g., GKT136901 and GKT137831), which are
structurally similar to the triazolo pyrimidines, inhibit Nox1-,
Nox4-, and Nox5-NADPH oxidases, and are orally bio-available,
have a safe profile, and appear to lack significant off target effects
(Laleu et al., 2010).
The flavonoid derivative S17834 was proposed to be a NADPH
oxidase inhibitor based on its ability to inhibit superoxide
production by cultured human umbilical vein endothelial cells
(HUVEC) and in isolated endothelial cell membranes, which
express Nox2- and/or Nox4-NADPH oxidase isoforms (Cayatte
et al., 2001). Ebselen and several of its selenium-containing
analogs have been identified as inhibitors of Nox2 and Nox1
oxidase, with one analog (JM-77b) exhibited potential Nox2
selectivity. Notably, the Nox inhibitory effect of ebselen occurred
at concentrations well below those at which it functions as a
Gpx mimetic, which would allow it to be used as ‘specific Nox
inhibitor’ (Muller et al., 1984). However, the Gpx properties
(and ONOO− scavenging properties) of ebselen clearly could
be considered advantageous in the setting of oxidative stress.
Another potential advantage of ebselen is that it orally available
and appears to have a safe profile (Yamaguchi et al., 1998).
Other promising NADPH oxidase inhibitors include fulvene-
5, triphenylmethane derivatives (e.g., Brilliant green), grindelic
acid, and ML171 (also known as 2-acetylphenothiazine; recently
reviewed in (Altenhofer et al., 2015; Table 1).
It is clear therefore that although significant progress has
been made over the past decade or so, more research is needed
to identify fully isoform selective Nox inhibitors with favorable
bioavailability. Further insight into the molecular structure of
the Nox catalytic subunits, their interaction with other NADPH
oxidase subunits, and how the Nox’s differ from each other, is
pivotal for the development of the next generation of selective
inhibitors.
CONCLUSION AND PERSPECTIVES
From the evidence outlined in this review, it is apparent
that oxidative stress may be a contributor to some of the
features of arteriopathy associated with both non-amyloid and
amyloid forms of cerebral SVD, and its risk factors (Figure 1).
Moreover, there is ample evidence of its potential contribution
to ischemia-induced brain injury and cognitive impairment,
important manifestations of cerebral SVD. Compelling evidence
points toward the Nox2-NADPH oxidase isoforms, as a key
mediator of oxidative damage in the brain and its circulation.
However, future work is needed to evaluate the contribution
of other NADPH oxidase isoforms (e.g., Nox1- and Nox4-
containing isoforms), as well as the importance of other sources
of ROS such as the mitochondria, COX and uncoupled eNOS.
This latter point notwithstanding, ROS are clearly compelling
targets for the prevention and treatment of cerebral SVD.
Moreover, the concept of inhibiting the production of ROS,
by the NADPH oxidases for example, should offer advantages
of conventional anti-oxidants. The NADPH oxidases have
been linked to numerous vascular-related diseases and as such
the design of novel selective NADPH oxidase inhibitors is
currently an area of intense research focus. However, a major
challenge in the development of such agents will be the
retainment of at least some NADPH oxidase activity for normal
immunological defense and for the physiological regulation of
cerebral vascular function. Lastly, it is important to acknowledge
that the majority of the evidence discussed in this review
comes from experimental models of cerebral SVD and risk
factors. As such, an essential goal of future work will be
to elucidate the extent to which these experimental findings
translate to the human scenario, and whether therapeutic
approaches to alleviate oxidative stress provide real benefits
with respect to reducing cerebral vascular events and cognitive
impairment.
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